Short interest for OrthoPediatrics gives investors a sense of the degree to which investors are betting on the decline of OrthoPediatrics's stock. Short interest data is updated every two weeks.

OrthoPediatrics Stock (NASDAQ:KIDS), Short Interest Report

OrthoPediatrics

OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AEYE

ARHS

BURL

CMPO

CRBP

DAVE

DXPE

EHAB

ETWO

HNST

KIDS

OSPN

TROX

YEXT

U.S. stocks were higher, with the Dow Jones index gaining more than 150 points on Thursday.

American Eagle Reports Upbeat Earnings, Joins Kroger, Burlington Stores And Other Big Stocks Moving Higher On Thursday

Price Target

Pre-Market Outlook

Analyst Ratings

GOOGL

INVH

Alphabet To Rally Over 10%? Here Are 10 Other Analyst Forecasts For Wednesday

Analyst Color

Earnings

Guidance

Health Care

General

Respiratory Infections Led OrthoPediatrics Miss Quarterly Sales Expectations, Analyst Calls It Transitory Issue

OrthoPediatrics Corp

OrthoPediatrics Corp. ("OrthoPediatrics") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has received the "Breakthrough Device" Designation from the Food and Drug Administration ("FDA") for its new eLLi surgical device, an implant designed to address severe pathology associated with Early Onset Scoliosis (EOS), which can be associated with thoracic insufficiency, a potentially life-threatening condition.&nbsp;eLLi aims to provide a non-invasive means of extending the growing rods that provides increased force, enhanced mechanical reliability, and superior distraction precision, while also addressing safety concerns associated with current technology. eLLi will allow surgeons a new alternative to address deformity of the growing spine with an advanced technology that will complement our efforts to build a platform of EOS technologies.&nbsp; We are proud to have an expert design team comprised of surgeons who have dedicated their careers to treating these unique patients.&nbsp; &nbsp;
According to the FDA, the Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The Breakthrough Program is intended to help patients have more timely access to medical devices by expediting their development, assessment, and review, while preserving the statutory standards for premarket approval, 510(k) clearance, and De Novo marketing authorization, consistent with the Agency's mission to protect and promote public health.
David Bailey, OrthoPediatrics' President &amp; CEO, commented, "Receiving the Breakthrough Device designation from the FDA is a great achievement for our team. This innovative product will be a great addition to our suite of products for pediatric patients with Scoliosis and represents our commitment to continuous innovation and advancing healthcare for children all over the world. I'm incredibly proud of my colleagues for all the work they are doing to deliver novel technologies to our surgeon customers and the KIDS they treat!"&nbsp;&nbsp;&nbsp;

Biotech

OrthoPediatrics Corp. Receives "Breakthrough Device" Designation From FDA For eLLi Growing Rod System For Pediatric Patients With Scoliosis

Analysts' ratings for OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for OrthoPediatrics, revealing an average target of $36.83, a high estimate of $50.00, and a low estimate of $31.00. Observing a 8.32% increase, the current average has risen from the previous average price target of $34.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1712782867_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive OrthoPediatrics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$37.00</td>
<td>-</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$32.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$37.00</td>
<td>-</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Kaila Krum</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$31.00</td>
<td>$39.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to OrthoPediatrics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OrthoPediatrics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for OrthoPediatrics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of OrthoPediatrics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KIDS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on OrthoPediatrics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About OrthoPediatrics</h2>
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
<h3>Financial Insights: OrthoPediatrics</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining OrthoPediatrics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 21.36% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: OrthoPediatrics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -17.79%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): OrthoPediatrics's ROE stands out, surpassing industry averages. With an impressive ROE of -1.78%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.54%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.03, OrthoPediatrics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: OrthoPediatrics In The Eyes Of 6 Experts

Needham analyst Mike Matson reiterates OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) with a Buy and maintains $37 price target.

Reiteration

Needham Reiterates Buy on OrthoPediatrics, Maintains $37 Price Target

Truist Securities analyst Samuel Brodovsky maintains OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) with a Hold and raises the price target from $31 to $32.

Truist Securities Maintains Hold on OrthoPediatrics, Raises Price Target to $32

OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for OrthoPediatrics, revealing an average target of $38.2, a high estimate of $50.00, and a low estimate of $31.00. Marking an increase of 8.12%, the current average surpasses the previous average price target of $35.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1709845252_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of OrthoPediatrics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$37.00</td>
<td>-</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Kaila Krum</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$31.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$39.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to OrthoPediatrics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OrthoPediatrics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of OrthoPediatrics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/KIDS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on OrthoPediatrics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About OrthoPediatrics</h2>
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
<h3>OrthoPediatrics's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, OrthoPediatrics showcased positive performance, achieving a revenue growth rate of 14.37% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: OrthoPediatrics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -11.49%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -1.22%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): OrthoPediatrics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -1.06%, the company showcases efficient use of assets and strong financial health.
Debt Management: OrthoPediatrics's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For OrthoPediatrics

Stifel analyst Rick Wise maintains OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) with a Buy and raises the price target from $32 to $34.

Stifel Maintains Buy on OrthoPediatrics, Raises Price Target to $34

WIIM

OrthoPediatrics shares are trading higher after the company reported better-than-expected Adj. EPS results and reiterated FY24 revenue guidance above estimates.

U.S. stocks were higher, with the Dow Jones index gaining more than 150 points on Thursday.
Shares of American Eagle Outfitters, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aeo#NYSE">AEO</a>) rose during Thursday&rsquo;s session after the company reported better-than-expected fourth-quarter earnings and issued strong three-year <a href="https://www.benzinga.com/quote/AEO/earnings">revenue outlook strategy</a>.
American Eagle Outfitters posted adjusted earnings of 61 cents per share, beating market estimates of 50 cents per share. The company&rsquo;s quarterly sales came in at $1.68 billion versus estimates of $1.66 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
American Eagle shares gained 5.4% to $24.72 on Thursday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>MoneyLion Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ml#NYSE">ML</a>) rose 28.3% to $67.43 following strong quarterly sales.</li>
<li>CompoSecure, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmpo#NASDAQ">CMPO</a>) jumped 27.5% to $5.99 as the company reported better-than-expected fourth-quarter financial results on Wednesday.</li>
<li>Rush Street Interactive, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rsi#NYSE">RSI</a>) surged 25.6% to $6.77 as the company reported better-than-expected fourth-quarter financial results and issued strong revenue guidance for 2024.</li>
<li>OneSpan Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ospn#NASDAQ">OSPN</a>) rose 24.9% to $11.97 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crbp#NASDAQ">CRBP</a>) gained 23.2% to $41.35.</li>
<li>Enhabit, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ehab#NASDAQ">EHAB</a>) surged 21.9% to $9.58 following strong quarterly results.</li>
<li>Rentokil Initial plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rto#NYSE">RTO</a>) climbed 19.2% to $32.94 after the company reported better-than-expected FY23 financial results.</li>
<li>Wave Life Sciences Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wve#NYSE">WVE</a>) rose 18.8% to $7.47. HC Wainwright &amp; Co. analyst Andrew Fein maintained WAVE Life Sciences with a Buy and raised the price target from $8 to $15.</li>
<li>The Honest Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hnst#NASDAQ">HNST</a>) gained 18.5% to $3.7301 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Dave Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dave#NYSE">DAVE</a>) gained 18.2% to $37.38.</li>
<li>The Chemours Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cc#NYSE">CC</a>) rose 16.5% to $25.67.</li>
<li>Arhaus, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arhs#NASDAQ">ARHS</a>) climbed 15.2% to $14.77 following upbeat quarterly results.</li>
<li>AudioEye, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aeye#NASDAQ">AEYE</a>) shares rose 13.8% to $7.89 after the company reported mixed fourth-quarter financial results and issued guidance.</li>
<li>Kronos Worldwide, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kro#NYSE">KRO</a>) rose 13.5% to $9.82 following upbeat quarterly results.</li>
<li>OrthoPediatrics Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kids#NASDAQ">KIDS</a>) gained 13.1% to $ 30.45 following upbeat quarterly earnings.</li>
<li>Avangrid, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/agr#NYSE">AGR</a>) rose 12.7% to $36.15 after the company announced that the Unaffiliated Committee of its Board of Directors received a non-binding proposal from Iberdrola to acquire all common shares that it or its affiliates do not own for $34.25 in cash per share.</li>
<li>John Wiley &amp; Sons, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wly#NYSE">WLY</a>) surged 11.5% to $36.92 following better-than-expected quarterly results.</li>
<li>E2open Parent Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/etwo#NYSE">ETWO</a>) rose 10.5% to $4.4750. E2open announced initiation of a strategic review.</li>
<li>DXP Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxpe#NASDAQ">DXPE</a>) gained 9.3% to $38.31 after reporting a fourth-quarter profit..</li>
<li>Novo Nordisk A/S (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvo#NYSE">NVO</a>) gained 8.6% to $ 135.51 after the company announced that a Phase 1 trial of its experimental drug Amycretin showed that participants lost 13.1% of their weight after 12 weeks.</li>
<li>ASE Technology Holding Co., Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/asx#NYSE">ASX</a>) rose 8% to $ 11.46.</li>
<li>Burlington Stores, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/burl#NYSE">BURL</a>) gained 7% to $220.15 after the company reported better-than-expected fourth-quarter financial results and issued FY24 adjusted EPS guidance.</li>
<li>The Kroger Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kr#NYSE">KR</a>) climbed 6.9% to $53.99 after the company reported fourth-quarter EPS above estimates.</li>
<li>Yext, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/yext#NYSE">YEXT</a>) shares rose 6.1% to $6.32 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Tronox Holdings plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/trox#NYSE">TROX</a>) rose 5.8% to $15.88.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/24/03/37533122/micron-to-rally-more-than-25-here-are-10-top-analyst-forecasts-for-thursday"> Micron To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Thursday </a>

JMP Securities analyst David Turkaly reiterates OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) with a Market Outperform and maintains $50 price target.

JMP Securities Reiterates Market Outperform on OrthoPediatrics, Maintains $50 Price Target

OrthoPediatrics Reiterates 2024 Guidance Range $197M-$200M vs $182.9M Est.

OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) reported quarterly losses of $(0.230) per share which beat the analyst consensus estimate of $(0.280) by 17.86 percent. This is a 28.13 percent increase over losses of $(0.320) per share from the same period last year. The company reported quarterly sales of $37.613 million which missed the analyst consensus estimate of $37.733 million by 0.32 percent. This is a 21.36 percent increase over sales of $30.994 million the same period last year.

Earnings Beats

Earnings Misses

OrthoPediatrics Q4 2023 Adj EPS $(0.230) Beats $(0.280) Estimate, Sales $37.613M Miss $37.733M Estimate

OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) reported its Q4 earnings results on Wednesday, March 6, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
OrthoPediatrics beat estimated earnings by 18.0%, reporting an EPS of $-0.23 versus an estimate of $-0.28.
Revenue was up $6.62 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.09 which was followed by a 2.0% increase in the share price the next day.
Here's a look at OrthoPediatrics's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.22</td>
<td>-0.19</td>
<td>-0.36</td>
<td>-0.25</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.13</td>
<td>-0.19</td>
<td>-0.29</td>
<td>-0.32</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>40.37M</td>
<td>39.11M</td>
<td>29.30M</td>
<td>32.62M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>39.97M</td>
<td>39.56M</td>
<td>31.59M</td>
<td>30.99M</td>
</tr>
</tbody>
</table>

To track all earnings releases for OrthoPediatrics <a href="https://www.benzinga.com/quote/KIDS/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: OrthoPediatrics Q4 Earnings

<h3>Companies Reporting Before The Bell</h3>
&bull; CTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTS#NYSE">CTS</a>) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.
&bull; Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) is likely to report quarterly earnings at $0.32 per share on revenue of $2.28 billion.
&bull; JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) is likely to report quarterly earnings at $0.63 per share on revenue of $42.16 billion.
&bull; Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $326.63 million.
&bull; Sotherly Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHO#NASDAQ">SOHO</a>) is projected to report earnings for its fourth quarter.
&bull; Thor Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) is estimated to report quarterly earnings at $0.67 per share on revenue of $2.27 billion.
&bull; Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $86.80 million.
&bull; VersaBank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBNK#NASDAQ">VBNK</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $22.43 million.
&bull; Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) is expected to report quarterly earnings at $2.83 per share on revenue of $1.43 billion.
&bull; Brown Forman Inc Class B Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) is expected to report quarterly earnings at $0.56 per share on revenue of $1.12 billion.
&bull; WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is likely to report quarterly loss at $0.23 per share on revenue of $19.86 million.
&bull; Yatsen Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YSG#NYSE">YSG</a>) is projected to report earnings for its fourth quarter.
&bull; iShares $ Short Duration Corp Bond UCITS ETF USD (Dist) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDIG#NASDAQ">SDIG</a>) is projected to report quarterly loss at $0.98 per share on revenue of $22.21 million.
&bull; InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) is expected to report quarterly loss at $0.19 per share on revenue of $1.63 million.
&bull; Korn Ferry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFY#NYSE">KFY</a>) is estimated to report quarterly earnings at $0.99 per share on revenue of $658.50 million.
&bull; Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $37.71 million.
&bull; PureCycle Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) is projected to report quarterly loss at $0.23 per share on revenue of $180 thousand.
&bull; Xeris Biopharma Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XERS#NASDAQ">XERS</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $43.55 million.
&bull; Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) is expected to report quarterly loss at $0.07 per share on revenue of $126.13 million.
&bull; Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $20.47 million.
&bull; NeueHealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEUE#NYSE">NEUE</a>) is estimated to report quarterly loss at $4.16 per share on revenue of $283.44 million.
&bull; Campbell Soup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NYSE">CPB</a>) is projected to report quarterly earnings at $0.77 per share on revenue of $2.44 billion.
&bull; EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) is projected to report quarterly loss at $0.18 per share on revenue of $44.03 million.
&bull; Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) is estimated to report quarterly loss at $2.01 per share on revenue of $55.25 million.
&bull; BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) is expected to report quarterly loss at $0.01 per share on revenue of $8.42 million.
&bull; Fusion Fuel Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) is estimated to report quarterly loss at $0.40 per share on revenue of $1.75 million.
&bull; European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $54.08 million.
&bull; REV Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NYSE">REVG</a>) is likely to report quarterly earnings at $0.15 per share on revenue of $579.42 million.
&bull; United Natural Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) is likely to report quarterly loss at $0.01 per share on revenue of $7.87 billion.
&bull; Berry Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRY#NASDAQ">BRY</a>) is projected to report quarterly earnings at $0.24 per share on revenue of $182.37 million.
&bull; Brown Forman Inc Class A Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) is estimated to report earnings for its third quarter.
&bull; Trinity Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIN#NASDAQ">TRIN</a>) is estimated to report quarterly earnings at $0.54 per share on revenue of $46.42 million.
&bull; Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) is expected to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; Descartes Systems Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGX#NASDAQ">DSGX</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $144.29 million.
&bull; Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) is estimated to report quarterly loss at $0.19 per share on revenue of $293.53 million.
&bull; Fortuna Silver Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSM#NYSE">FSM</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $261.00 million.
&bull; Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) is estimated to report quarterly loss at $1.27 per share on revenue of $340 thousand.
&bull; Companhia Siderurgica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SID#NYSE">SID</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $2.32 billion.
&bull; Global X Silver Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIL#NYSE">SIL</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $44.09 million.
&bull; TDCX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDCX#NYSE">TDCX</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $121.92 million.
&bull; Vermilion Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VET#NYSE">VET</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $440.69 million.
&bull; VSE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEC#NASDAQ">VSEC</a>) is expected to report quarterly earnings at $0.75 per share on revenue of $234.91 million.
&bull; Victoria&#39;s Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) is projected to report quarterly earnings at $2.47 per share on revenue of $2.09 billion.
&bull; SandRidge Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SD#NYSE">SD</a>) is likely to report earnings for its fourth quarter.
&bull; CPS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSH#NASDAQ">CPSH</a>) is projected to report earnings for its fourth quarter.
&bull; Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) is expected to report quarterly loss at $0.23 per share on revenue of $61.45 million.
&bull; KLX Energy Services Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLXE#NASDAQ">KLXE</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $212.97 million.
&bull; Culp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CULP#NYSE">CULP</a>) is likely to report quarterly loss at $0.16 per share on revenue of $59.49 million.
&bull; GEN Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENK#NASDAQ">GENK</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $43.95 million.
&bull; MISTRAS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MG#NYSE">MG</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $174.28 million.
&bull; IDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDT#NYSE">IDT</a>) is projected to report earnings for its second quarter.
&bull; FRP Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPH#NASDAQ">FRPH</a>) is projected to report earnings for its fourth quarter.
&bull; Global Water Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWRS#NASDAQ">GWRS</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $12.00 million.
&bull; NeoGames (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGMS#NASDAQ">NGMS</a>) is projected to report quarterly loss at $0.07 per share on revenue of $54.53 million.
&bull; Hamilton Beach Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBB#NYSE">HBB</a>) is estimated to report earnings for its fourth quarter.
&bull; Amplify Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPY#NYSE">AMPY</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $76.22 million.
&bull; Pampa Energia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAM#NYSE">PAM</a>) is likely to report quarterly loss at $0.09 per share on revenue of $421.19 million.
&bull; Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $280 thousand.
&bull; Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) is expected to report quarterly loss at $0.12 per share on revenue of $70 thousand.
&bull; HighPeak Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPK#NASDAQ">HPK</a>) is expected to report quarterly earnings at $0.65 per share on revenue of $339.52 million.
&bull; BRC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $123.75 million.
&bull; MDxHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXH#NASDAQ">MDXH</a>) is likely to report quarterly loss at $0.11 per share on revenue of $18.14 million.
&bull; NACCO Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NC#NYSE">NC</a>) is estimated to report earnings for its fourth quarter.
&bull; Enhabit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHAB#NYSE">EHAB</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $260.16 million.
&bull; Intrepid Potash (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPI#NYSE">IPI</a>) is projected to report quarterly loss at $0.06 per share on revenue of $43.57 million.
&bull; OneSpan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSPN#NASDAQ">OSPN</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $58.26 million.
&bull; Honest Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNST#NASDAQ">HNST</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $84.14 million.
&bull; SilverCrest Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SILV#AMEX">SILV</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $44.09 million.
&bull; AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $7.93 million.
&bull; comScore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) is likely to report quarterly earnings at $0.20 per share on revenue of $97.69 million.
&bull; Viemed Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $50.00 million.
&bull; Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) is projected to report earnings for its third quarter.
&bull; ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $20.98 million.
&bull; Whitestone REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSR#NYSE">WSR</a>) is projected to report earnings for its fourth quarter.
&bull; Aris Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) is estimated to report earnings for its fourth quarter.
&bull; OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) is expected to report quarterly loss at $0.28 per share on revenue of $37.73 million.
&bull; Invesco National AMT-Free Municipal Bond ETFo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PZA#NYSE">PZA</a>) is estimated to report earnings for its fourth quarter.
&bull; Hudson Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDSN#NASDAQ">HDSN</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $40.28 million.
&bull; Stabilis Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNG#NASDAQ">SLNG</a>) is projected to report earnings for its fourth quarter.
&bull; Airgain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRG#NASDAQ">AIRG</a>) is projected to report quarterly loss at $0.20 per share on revenue of $10.00 million.
&bull; Finance of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOA#NYSE">FOA</a>) is projected to report quarterly loss at $0.08 per share on revenue of $63.22 million.
&bull; Yext (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) is likely to report quarterly earnings at $0.07 per share on revenue of $100.24 million.
&bull; TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) is expected to report quarterly earnings at $0.48 per share on revenue of $33.13 million.
&bull; CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $96.49 million.
&bull; Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>) is expected to report quarterly earnings at $0.29 per share on revenue of $222.52 million.
&bull; Cyber Hornet S&amp;P 500 and Bitcoin 75/25 Strategy ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZZZ#NASDAQ">ZZZ</a>) is likely to report quarterly earnings at $0.53 per share on revenue of $247.43 million.
&bull; Ellington Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EARN#NYSE">EARN</a>) is projected to report quarterly earnings at $0.23 per share on revenue of $2.46 million.
&bull; Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) is expected to report quarterly loss at $0.72 per share on revenue of $29.34 million.
&bull; Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $73.40 million.
&bull; Rush Street Interactive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSI#NYSE">RSI</a>) is likely to report quarterly loss at $0.03 per share on revenue of $178.56 million.
&bull; Hamilton Insurance Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HG#NYSE">HG</a>) is expected to report quarterly earnings at $0.65 per share on revenue of $15.30 million.
&bull; Infinera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INFN#NASDAQ">INFN</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $437.34 million.
&bull; Riley Exploration Permian (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/REPX#AMEX">REPX</a>) is estimated to report quarterly earnings at $1.60 per share on revenue of $94.75 million.
&bull; Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) is expected to report quarterly loss at $0.43 per share on revenue of $15.45 million.
&bull; Miller Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLR#NYSE">MLR</a>) is projected to report earnings for its fourth quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ADAP

AIRG

AMPY

ARIS

BRCC

BWAY

CDXC

CPSH

CULP

DSGX

EARN

EVGO

EWCZ

FRPH

GENI

GENK

GROV

GWRS

HDSN

HIPO

HTOO

INFN

KEQU

KLXE

KMDA

LVLU

MDXH

NEUE

NEXN

NGMS

NSPR

PowerShares Insured Municipal Bond Portfolio

REPX

REVG

SCOR

SDIG

SGHC

SILV

SLNG

SOHO

SPIR

TDCX

TLPH

TPVG

TRIN

UNFI

VBNK

VSCO

VSEC

XERS

ZYME

Earnings Scheduled For March 6, 2024

OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-03-06. Here's what investors need to know before the announcement.
Analysts estimate that OrthoPediatrics will report an earnings per share (EPS) of $-0.28. 
OrthoPediatrics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.09, which was followed by a 2.19% increase in the share price the next day.
Here's a look at OrthoPediatrics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.22</td>
<td>-0.19</td>
<td>-0.36</td>
<td>-0.25</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.13</td>
<td>-0.19</td>
<td>-0.29</td>
<td>-0.32</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>-5.0%</td>
<td>-10.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709651101_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of OrthoPediatrics were trading at $27.68 as of March 04. Over the last 52-week period, shares are down 33.72%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/KIDS/earnings">To track all earnings releases for OrthoPediatrics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For OrthoPediatrics

OrthoPediatrics Launches RESPONSE Rib And Pelvic Fixation System For EOS Scoliosis

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $38.4, a high estimate of $50.00, and a low estimate of $31.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 12.73%. 
<img src="https://www.benzinga.com/files/images/story/2024/1706184047_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of OrthoPediatrics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kaila Krum</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$31.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$39.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$37.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to OrthoPediatrics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of OrthoPediatrics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for OrthoPediatrics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into OrthoPediatrics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KIDS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on OrthoPediatrics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into OrthoPediatrics's Background</h2>
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
<h3>Understanding the Numbers: OrthoPediatrics's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: OrthoPediatrics's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 14.37%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: OrthoPediatrics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -11.49%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -1.22%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): OrthoPediatrics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.06%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.0.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 5 Analyst Evaluations For OrthoPediatrics

Truist Securities analyst Kaila Krum downgrades OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) from Buy to Hold and lowers the price target from $39 to $31.

Downgrades

Truist Securities Downgrades OrthoPediatrics to Hold, Lowers Price Target to $31

OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2023, and issued 2024 financial guidance. &nbsp;
During the fourth quarter of 2023 the Company helped nearly 20,000 children and since inception the Company has now helped over 710,000 children. Including Boston O&amp;P, the combined organizations have helped more than 1 million kids.
Preliminary unaudited fourth quarter 2023 net revenue is expected to be $37.6 million, representing growth of 21% compared to $31.0 million in the fourth quarter of 2022. Preliminary domestic fourth quarter net revenue is expected to be $28.3 million, representing 24% growth compared to the prior year period, and international net revenue is expected to be $9.3 million, representing 13% growth compared to the prior year period.
Preliminary unaudited full year 2023 net revenue is expected to be $148.7 million, representing growth of 22% compared to $122.3 million in 2022. Preliminary full year domestic net revenue is expected to be $111.0 million, representing 20% annual growth and international net revenue is expected to be $37.7 million, representing 26% annual growth.
"Despite historically high rates of respiratory illness in the back half of the fourth quarter, we produced strong revenue growth of 21%, reflecting continued commercial and operational execution," commented David Bailey, President &amp; CEO of OrthoPediatrics. "OrthoPediatrics remains in its strongest strategic position of all time, supported by an expanding user base, robust product portfolio, recent acquisitions, and a growing international presence."
Post closing of the Boston O&amp;P acquisition on January 5, 2024, OrthoPediatrics cash and restricted cash balance is approximately $60 million. OrthoPediatrics entered into a new credit agreement with MidCap Financial, consisting of term loan and revolving loan. The term loan provides up to $30 million of capital and the revolving loan provides up to an additional $50 million, for a total consideration of $80 million. In advance of the acquisition, OrthoPediatrics drew an initial $10 million from the term loan.
2024 Financial Guidance OrthoPediatrics projects 2024 revenue to be in the range of $197 million to $200 million, including revenue contribution from Boston O&amp;P and representing 32% to 34% growth compared to full year 2023 preliminary unaudited net revenue. The acquisition is expected to be accretive to OrthoPediatrics adjusted EBITDA in 2024 and accretive to revenue growth in 2025, following the completion of integration activities. Boston O&amp;P's recent annual historical revenue is approximately $25 million. Boston O&amp;P was a customer of OrthoPediatrics, purchasing the MD Orthopedics clubfoot specialty brace as well as a supplier to OrthoPediatrics, manufacturing the recently launched DF2 brace.
The Company plans to release its fourth quarter and full year 2023 financial results and provide additional commentary on its financial outlook in March. The quarterly and annual preliminary unaudited net revenue estimates for 2023 included in this press release are prior to the completion of review and audit procedures by the Company's independent registered public accounting firm and are therefore subject to adjustment.

OrthoPediatrics Corp. Announces Preliminary Unaudited Financial Highlights For Q4 & FY23; Sees Q4 Revenue $37.6M Vs $37.77M Est.; FY23 Revenue $148.7M Vs $148.88M Est.; Sees FY24 Revenue $197M-$200M Vs $177.7M Est

Combined organizations have helped more than 1 million kids &nbsp;
Expands Specialty Bracing Division with pediatric orthotic management business&nbsp;offering leading technology and pediatric care through dedicated clinics
Closes $80 million debt financing to support acquisition and future business requirements
WARSAW, Ind., Jan. 08, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp.&nbsp;("OrthoPediatrics" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that it has acquired Boston Orthotics&nbsp;&amp; Prosthetics ("Boston O&amp;P"), a leader in pediatric orthotic management for over 50 years. Additionally, in advance of the acquisition, the Company closed a debt financing with MidCap Financial which provides up to $80 million of capital, through the combination of a term loan and revolving loan, replacing its prior unused $50 million line of credit.
Boston Orthotics&nbsp;&amp; Prosthetics is a profitable company offering leading bracing, orthotic and prosthetic technology for the non-operative treatment of children whose lives have been impacted by scoliosis, plagiocephaly, and various neuromuscular disorders. The custom, patient specific Boston Brace for Scoliosis, lower limb orthoses and Dynamic Movement Orthoses (DMO), as well as the Boston Band for plagiocephaly are among the most advanced, individualized braces available to treat pediatric orthopedic conditions today. Boston O&amp;P's products will expand OrthoPediatrics' existing Specialty Bracing division ("OPSB"), a flagship house of brands and innovative products, to further penetrate the largest segments of the $500 million U.S. pediatric orthopedic specialty bracing market. It is estimated 80% of pediatric orthopedic care happens before and after surgery.
"We are thrilled to announce the acquisition of Boston O&amp;P, an organization that shares our mission to help children whose lives have been impacted by orthopedic conditions. We are now the first company to have a role supporting the entire continuum of care for pediatric orthopedic patients. This opportunity significantly expands our newly launched OrthoPediatrics Specialty Bracing division and is reflective of the opportunity we saw with pediatric surgical implants at the Company's founding. The large majority of pediatric orthopedic patients are not surgical candidates, and specialty bracing remains an underserved market. Boston O&amp;P offers unique products designed specifically to address unmet pediatric needs in several of the largest non-surgical orthopedic treatment markets. Adding their complementary portfolio to our platform will offer additional options to our current surgeon customers to help manage patients before and after surgery," said Dave Bailey, Chief Executive Officer of OrthoPediatrics.
Partnering with world class medical facilities, including Boston Children's Hospital, Children's Hospital of Philadelphia, Nationwide Children's Hospital in Columbus, Ohio, and Phoenix Children's Hospital, Boston O&amp;P maintains 26 patient care clinics across the U.S.&nbsp;Boston O&amp;P's recent annual historical revenue is approximately $25 million.
"This acquisition enables us to serve more patients as an extension of our growth strategy to surround our pediatric orthopedic surgeon customers with the most comprehensive portfolio of pediatric orthopedic treatment devices. Mr. Bailey continued, "Combined, our businesses have helped over one million children globally and we look forward to helping the next million together by expanding the number of clinics and aggressively launching new products that meet unmet needs for children and their caregivers. Over time, we aspire to support all 300 high volume children's hospitals in the U.S."
Boston O&amp;P General Manager, Tom Morrissey echoed his excitement for the transaction, stating "We are very excited and proud to be joining the OrthoPediatrics team. It is truly amazing how similar the two companies are and in our shared passion for taking care of kids. We remain committed to improving the quality of pediatric orthotic and prosthetic care and related products kids receive, and the resources OrthoPediatrics will provide can expedite greatly the achievement of that mission. We cannot wait to get started to build the new OrthoPediatrics' newly launched Specialty Bracing division."
Transaction Details and Debt Financing
Under terms of the transaction, signed and closed on January&nbsp;5, 2024, OrthoPediatrics has acquired Boston O&amp;P for an upfront cash payment of $22 million. Post closing, OrthoPediatrics cash and restricted cash balance is approximately $60 million.
In advance of the acquisition, OrthoPediatrics entered into a new credit agreement with MidCap Financial, consisting of&nbsp;term loan and revolving loan. The term loan provides up to $30 million of capital and the revolving loan provides up to an additional $50 million, for a total availability of $80 million. The credit agreement replaces the previously unused $50 million line of credit with Squadron Capital. In advance of the acquisition, OrthoPediatrics drew an initial $10 million from the term loan.

OrthoPediatrics Corp. Announces Acquisition Of Boston Orthotics & Prosthetics For An Upfront Cash Payment Of $22M; Closes $80M Debt Financing To Support Acquisition And Future Business Requirements

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on MDxHealth (MDXH – Research Report), OrthoPediatric...

Analysts Conflicted on These Healthcare Names: MDxHealth (MDXH), OrthoPediatrics (KIDS) and Karuna Therapeutics (KRTX)

OrthoPediatrics Corp (KIDS) has provided an update. OrthoPediatrics Corp.'s executive team is gearing up for a series of presentations to investors...

OrthoPediatrics Corp Enhances Investor Relations Efforts

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on QuidelOrtho (QDEL – Research Report), OrthoPediatric...

Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), OrthoPediatrics (KIDS) and RegenXBio (RGNX)

OrthoPediatrics files $250M mixed securities shelf

Atrion Corporation Is Overvalued For The Direction Fundamentals Are Heading

OrthoPediatrics (KIDS) Receives a Buy from Piper Sandler

Don't expect pandemic backlog to fuel orthopedic sales, says Needham

Analyst Michael Matson of Needham maintained a Buy rating on OrthoPediatrics (KIDS – Research Report), retaining the price target of $37.00. Michae...

Strong Buy on OrthoPediatrics: Strategic Growth and Positive Market Outlook

Top 10 stocks with upwards and downwards daily percentage change - Piper Sandler

Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down

ACRV

AORT

ATEC

ATRC

ATRI

AVNS

AZTA

CAVA

CNMD

CUTR

EMBC

ENOV

FNWB

FVCB

GKOS

GMDAQ

GMED

IMUX

IRTC

ISRG

KRTX

LESL

LIVN

LPTX

NARI

NOVA

NRIX

OSUR

QDEL

RAPT

RENT

RGNX

RVMD

RXST

SIBN

SKYE

SRDX

TRML

TSHA

VCYT

XRAY

Press Releases

OrthoPediatrics Corp. Announces Acquisition of Boston Orthotics & Prosthetics

OrthoPediatrics Corp. Announces Preliminary Unaudited Financial Highlights for the Fourth Quarter & Full Year 2023

OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024

OrthoPediatrics Corp. Named One of the 2024 Best Places to Work in Indiana

OrthoPediatrics Corp. Launches New RESPONSE Rib and Pelvic Fixation System for EOS Scoliosis

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results

OrthoPediatrics Corp. to Participate in the 23rd Annual Needham Virtual Healthcare Conference

OrthoPediatrics Corp. to Highlight its Pediatric Scoliosis Solutions at 8th Annual International Children's Spine Symposium (ICSS)

OrthoPediatrics Corp. to Report First Quarter 2024 Financial Results on May 7, 2024

OrthoPediatrics Corp. Receives "Breakthrough Device" Designation from FDA for eLLi™ Growing Rod System for Pediatric Patients with Scoliosis

Align Tech

Atrion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

OrthoPediatrics Stock (NASDAQ:KIDS), Short Interest Report

People Also Watch